ClinicalTrials.gg
TerminatedNCT02759315Updated Jun 26, 2019Results posted

Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)

A Phase 2 interventional study of Uprifosbuvir 450 mg and Ruzasvir 60 mg in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated based on review of Phase 2 efficacy data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies in Hepatitis C, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · Merck & Co., Inc.

Enrollment
28th of 72
160 · median 113
Started
2016
with 1 other
Phase 2
16 of 110
none open now
Registered
110th of 110
by date

Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 28th largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2016, is one of 16 in phase 2, and was the 110th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc is open now. The open studies under Hepatitis C, Chronic, anywhere →

Where they have run

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc as a file.
02

Study summary

This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3, GT4, GT5, or GT6 infection. The impact of the study treatment regimen on the percentage of participants with undetectable HCV ribonucleic acid [RNA] 12 weeks after completing study treatment (SVR12) will be evaluated.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has virus (HCV) ribonucleic acid (RNA) at the time of screening
  • Has documented chronic HCV genotype (GT)1, GT2, GT3, GT4, GT5, or GT6 with no evidence of non-typeable or mixed GT infection
  • Is otherwise healthy as determined by the medical history, physical examination, (ECG), and clinical laboratory measurements performed at the time of screening
  • Has absence of cirrhosis or has compensated cirrhosis
  • Is HCV treatment-naïve or has experienced virologic failure after completing a prior interferon-containing regimen
  • Is of non- or agrees to avoid becoming pregnant or impregnating a partner beginning at least 2 weeks prior to administration of the initial dose of study drug and for 14 days after the last dose of study drug
  • For (HIV) co-infected participants: is not currently on antiretroviral therapy (ART) and has no plans to initiate ART treatment while participating in this study Or has well-controlled HIV on ART

Exclusion criteria

Exclusion Criteria:

  • Is mentally or legally incapacitated, has significant emotional problems (at screening or expected during the study) or has a history of a psychiatric disorder that would interfere with the study procedures.
  • Has evidence of decompensated liver disease manifested by the presence of or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver disease
  • Is Class B or C or has a Pugh-Turcotte (CPT) score >6 if cirrhotic
  • Is co-infected with Virus
  • Has a history of opportunistic infection in the preceding 6 months prior to screening if co-infected with
  • Has a history of ≤5 years prior to study start (except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ) or is under evaluation for other active or suspected malignancy
  • Has cirrhosis and liver imaging within 6 months prior to study start showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC
  • Is taking any medications or herbal supplements restricted by the study entry criteria in the period from ≤2 weeks prior to study start through 2 weeks after the last dose of study drug
  • Has clinically-relevant drug or alcohol abuse within 12 months of study start
  • Has participated in any clinical study of an product within 30 days prior to the first dose of study drug
  • Is female and is pregnant or breastfeeding, or expecting to conceive or donate eggs from at least 2 weeks prior to study start and 14 days after the last dose of study drug
  • Is male and is expecting to donate sperm from at least 2 weeks prior to Day 1 until 14 days after the last dose of study drug
  • Has or has had any of the following: organ transplants (including hematopoietic stem cell transplants) other than cornea and hair; poor venous access; history of gastric surgery; or history of malabsorption disorders
  • Has any cardiac abnormalities/dysfunction including but not limited to: unstable angina; unstable congestive heart failure; or unstable arrhythmia
  • Has a history of a medical/surgical condition that resulted in hospitalization within 3 months prior to study start, other than for minor elective procedures
  • Has any medical condition requiring, or likely to require, chronic systemic administration of , tumor necrosis factor (TNF) antagonists, or other drugs during the study
  • Has evidence of history of chronic hepatitis not caused by
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg

    Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.

    Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg

  • Experimental
    GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg

    Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.

    Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg

  • Experimental
    GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg

    Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.

    Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg

  • Experimental
    GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg

    Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.

    Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg

  • Experimental
    GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg

    Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.

    Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg

  • Experimental
    GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg

    Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.

    Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg

Interventions

  • 450 mg administered as 3 x 150 mg oral tablets

    Also known as: MK-3682

  • 60 mg administered as 6 x 10 mg oral capsules

    Also known as: MK-8408

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)

    The percentage of participants in each arm achieving SVR12 was determined. SVR12 was defined as HCV ribonucleic acid (RNA) levels in plasma \< lower limit of quantification (LLOQ) 12 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.

    Time frame: Week 24 (12 weeks after completing study therapy)

  2. Percentage of Participants With ≥1 Adverse Events (AEs)

    The percentage of participants experiencing an AE during the treatment period and first 2 weeks of follow-up was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Week 14 (up to 2 weeks after completing study therapy)

  3. Percentage of Participants Withdrawing From Study Therapy Due to an AE

    The percentage of participants discontinuing from study therapy during the treatment period was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Week 12

  4. Percentage of Participants With ≥1 Events of Clinical Interest (ECIs)

    The percentage of participants with ECIs was determined. ECIs were defined as the following: 1) an overdose of study drug; 2) first instance of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>500 IU/L; 3) first instance of ALT or AST \>3x nadir and \>3x upper limit of normal (ULN); 4) first instance of estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2; or 4) first instance of serum creatinine \>1.3x ULN and elevated from baseline.

    Time frame: Up to Week 14 (up to 2 weeks after completing study therapy)

Secondary outcomes

  1. Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)

    The percentage of participants in each arm achieving SVR24 was determined. SVR24 was defined as HCV RNA levels in plasma \< LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. For SVR24, participants with GT1 infection were separated into GT1a or GT1b infection.

    Time frame: Week 36 (24 weeks after completing study therapy)

  2. Percentage of Participants With Virologic Failure (VF)

    The percentage of participants in each arm experiencing VF was determined. VF was defined as: 1) non-response (HCV RNA detected at end of treatment without HCV RNA \< LLOQ while on treatment); 2) rebound (\>1 log 10 IU/mL increase in HCV RNA from nadir while on treatment); 3) virologic breakthrough (HCV RNA ≥LLOQ after being \<LLOQ on treatment); or 4) relapse (HCV RNA ≥LLOQ after end of all study therapy after being undetectable at end of treatment); virologic failure could occur either on-treatment or relapse post-treatment. For VF, participants with GT1 infection were separated into GT1a or GT1b infection

    Time frame: 12 weeks after the end of all study therapy (24 weeks)

  3. Percentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR12

    The percentage of participants in each arm with baseline RAS achieving SVR12 was determined. Analysis of RAS in NS5A or NS5B at baseline was determined. SVR12 was defined as HCV RNA levels in plasma \< LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.

    Time frame: 12 weeks after the end of all study therapy (24 weeks)

07

Results

Posted Aug 6, 2018

Participant flow

Adult participants with hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, or 6 infection were enrolled at 5 study centers in the United States. Participants with HCV GT5 infection were initially intended for inclusion but none were enrolled.

Participant flow — Overall Study
MilestoneGT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Started692939203
Completed652829192
Not completed411011
Withdrew: Adverse event00010
Withdrew: Death00100
Withdrew: Lost to follow-up20400
Withdrew: Protocol violation01000
Withdrew: Study terminated prior to completion20501

Outcome measures

PrimaryPercentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)

The percentage of participants in each arm achieving SVR12 was determined. SVR12 was defined as HCV ribonucleic acid (RNA) levels in plasma \< lower limit of quantification (LLOQ) 12 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.

Time frame:
Week 24 (12 weeks after completing study therapy)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)
Percentage of ParticipantsGT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)97.1 (89.9 to 99.6)100.0 (87.7 to 100.0)76.9 (60.7 to 88.9)90.0 (68.3 to 98.8)66.7 (9.4 to 99.2)
PrimaryPercentage of Participants With ≥1 Adverse Events (AEs)

The percentage of participants experiencing an AE during the treatment period and first 2 weeks of follow-up was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to Week 14 (up to 2 weeks after completing study therapy)
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥1 Adverse Events (AEs)
Percentage of ParticipantsGT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Percentage of Participants With ≥1 Adverse Events (AEs)52.244.843.655.066.7
PrimaryPercentage of Participants Withdrawing From Study Therapy Due to an AE

The percentage of participants discontinuing from study therapy during the treatment period was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Withdrawing From Study Therapy Due to an AE
Percentage of ParticipantsGT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Percentage of Participants Withdrawing From Study Therapy Due to an AE0.03.40.05.00.0
SecondaryPercentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)

The percentage of participants in each arm achieving SVR24 was determined. SVR24 was defined as HCV RNA levels in plasma \< LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. For SVR24, participants with GT1 infection were separated into GT1a or GT1b infection.

Time frame:
Week 36 (24 weeks after completing study therapy)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)
Percentage of ParticipantsGT1a: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT1b: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)96.2100.075.090.066.7100.0
SecondaryPercentage of Participants With Virologic Failure (VF)

The percentage of participants in each arm experiencing VF was determined. VF was defined as: 1) non-response (HCV RNA detected at end of treatment without HCV RNA \< LLOQ while on treatment); 2) rebound (\>1 log 10 IU/mL increase in HCV RNA from nadir while on treatment); 3) virologic breakthrough (HCV RNA ≥LLOQ after being \<LLOQ on treatment); or 4) relapse (HCV RNA ≥LLOQ after end of all study therapy after being undetectable at end of treatment); virologic failure could occur either on-treatment or relapse post-treatment. For VF, participants with GT1 infection were separated into GT1a or GT1b infection

Time frame:
12 weeks after the end of all study therapy (24 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Virologic Failure (VF)
Percentage of ParticipantsGT1a: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT1b: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Percentage of Participants With Virologic Failure (VF)3.70.023.15.033.30.0
SecondaryPercentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR12

The percentage of participants in each arm with baseline RAS achieving SVR12 was determined. Analysis of RAS in NS5A or NS5B at baseline was determined. SVR12 was defined as HCV RNA levels in plasma \< LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.

Time frame:
12 weeks after the end of all study therapy (24 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR12
Percentage of ParticipantsGT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Percentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR1297.1100.097.494.766.6
PrimaryPercentage of Participants With ≥1 Events of Clinical Interest (ECIs)

The percentage of participants with ECIs was determined. ECIs were defined as the following: 1) an overdose of study drug; 2) first instance of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>500 IU/L; 3) first instance of ALT or AST \>3x nadir and \>3x upper limit of normal (ULN); 4) first instance of estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2; or 4) first instance of serum creatinine \>1.3x ULN and elevated from baseline.

Time frame:
Up to Week 14 (up to 2 weeks after completing study therapy)
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥1 Events of Clinical Interest (ECIs)
Percentage of ParticipantsGT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Overdose4.33.45.1——
Non-overdose ECI2.8—2.5——

Adverse events

Collected over Up to 36 weeks (up to 24 weeks after completing study treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg0/69 (0%)4/69 (5.8%)25/69 (36.2%)
GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg0/29 (0%)0/29 (0%)8/29 (27.6%)
GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg1/39 (2.6%)1/39 (2.6%)13/39 (33.3%)
GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg0/20 (0%)2/20 (10%)6/20 (30%)
GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventGT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Arthritis bacterialInfections and infestations0/690/290/391/200/3
Staphylococcal bacteraemiaInfections and infestations0/690/290/391/200/3
Urinary tract infectionInfections and infestations0/690/290/391/200/3
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/690/290/391/200/3
SciaticaNervous system disorders0/690/290/391/200/3
Acute kidney injuryRenal and urinary disorders0/690/290/391/200/3
Accidental overdoseInjury, poisoning and procedural complications0/690/291/390/200/3
MelaenaGastrointestinal disorders1/690/290/390/200/3
Oesophagitis haemorrhagicGastrointestinal disorders1/690/290/390/200/3
Upper gastrointestinal haemorrhageGastrointestinal disorders1/690/290/390/200/3
Most frequent other events
Showing 10 of 12
Most frequent other events
EventGT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg
Abdominal distensionGastrointestinal disorders0/690/290/390/201/3
FatigueGeneral disorders7/692/290/390/201/3
Upper respiratory tract infectionInfections and infestations1/691/290/390/201/3
Urinary tract infectionInfections and infestations3/691/291/391/201/3
InsomniaPsychiatric disorders0/690/290/391/201/3
NasopharyngitisInfections and infestations0/690/290/393/200/3
HeadacheNervous system disorders3/693/291/391/200/3
DiarrhoeaGastrointestinal disorders4/690/294/391/200/3
FlatulenceGastrointestinal disorders2/690/291/392/200/3
NauseaGastrointestinal disorders6/691/293/392/200/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mgTotal
Mean49.8 ± 10.757.2 ± 6.848.7 ± 10.356.5 ± 8.561.3 ± 1.551.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mgTotal
Female3310185167
Male36192115293
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT2: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT3: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT4: Uprifosbuvir 450 mg + Ruzasvir 60 mgGT6: Uprifosbuvir 450 mg + Ruzasvir 60 mgTotal
American Indian or Alaska Native000000
Asian000033
Native Hawaiian or Other Pacific Islander000000
Black or African American420107
White642739190149
More than one race100001
Unknown or Not Reported000000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. J Viral Hepat. 2019 Jun;26(6):675-684. doi: 10.1111/jvh.13079. Epub 2019 Mar 12. PubMed 30739366 ↗
  • Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11. PubMed 31108015 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Jul 2017, 14 months.

Results were first posted in Aug 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2016
First posted
May 3, 2016
StartActual
May 3, 2016
Primary completionActual
Jul 27, 2017
CompletionActual
Nov 16, 2017
Results first posted
Aug 6, 2018
Last update
Jun 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02759315
Responsible party
Sponsor
First posted
May 3, 2016
Start date
May 3, 2016
Primary completion
Jul 27, 2017
Completion
Nov 16, 2017
Results posted
Aug 6, 2018
Last update
Jun 26, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Uprifosbuvir · Ruzasvir

Start the discussion